Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Volume 73, Number 12, September 22, 2009
Right arrow Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Llufriu, S.
Right arrow Articles by Saiz, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Llufriu, S.
Right arrow Articles by Saiz, A.
Related Collections
Right arrow All Demyelinating disease (CNS)
Right arrow Multiple sclerosis
Right arrow Devic's syndrome
Right arrow Optic neuritis; see Neuro-ophthalmology/Optic Nerve
Right arrow Acute disseminated encephalomyelitis
NEUROLOGY 2009;73:949-953
© 2009 American Academy of Neurology

Plasma exchange for acute attacks of CNS demyelination

Predictors of improvement at 6 months

S. Llufriu, MD, J. Castillo, MD, Y. Blanco, MD, L. Ramió-Torrentà, MD, J. Río, MD, M. Vallès, MD, M. Lozano, MD, M. D. Castellà, MD, J. Calabia, MD, A. Horga, MD, F. Graus, MD, X. Montalban, MD and A. Saiz, MD

From the Neurology (S.L., Y.B., F.G., A.S.) and Hemotherapy-Hemostasis (M.L.) Services, Hospital Clínic, Universitat de Barcelona and Institut d’Investigació Biomèdica August Pi i Sunyer; Centre d’Esclerosi Múltiple de Catalunya (J.C., J.R., A.H., X.M.), CEM-Cat, Unitat de Neuroimmunologia Clínica, and Centre de Transfusió i Banc de Teixits (M.D.C.), Hospital Universitari Vall d’Hebron, Barcelona; and Neurology (L.R.-T.) and Nephrology (M.V., J.C.) Services, Hospital Josep Trueta, Girona, Spain.

Address correspondence and reprint requests to Dr. Albert Saiz, Service of Neurology, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain asaiz{at}clinic.ub.es

Background: Plasma exchange (PE) is used to treat severe episodes of CNS demyelination unresponsive to corticosteroids. Predictors of long-term response are not well known.

Methods: We retrospectively reviewed the medical records of 41 patients consecutively treated by PE between January 1995 and July 2007. The primary outcome was improvement at 6 months after PE defined as decrease of ≥1 point in the Expanded Disability Status Scale (EDSS) score for patients with EDSS ≤7.5 or 1.5 points with EDSS ≥8.0 or improvement of more than 2 lines in the visual acuity chart for patients with optic neuritis (ON).

Results: Twenty-five patients (61%) were women, and the median age was 33 years (range 14–57 years). Twenty-three (56%) had multiple sclerosis, 2 (5%) had clinically isolated syndrome, 2 (5%) had Marburg disease, 7 (17%) had acute disseminated encephalomyelitis, 4 (10%) had neuromyelitis optica, 2 (5%) had idiopathic ON, and 1 (2%) had idiopathic transverse myelitis. The median EDSS score before the attack was 1.0 (range 0–6.5). At PE onset, the median EDSS score was 7.0 (range 3.0–9.5). Sixteen patients (39%) improved at discharge, and 26 (63%) improved at 6 months. In the multivariate analysis, early initiation of PE (odds ratio [OR] 6.29, 95% confidence interval [CI] 1.18–52.96) and improvement at discharge (OR 7.32, 95% CI 1.21–44.38) were significantly associated with response at 6 months.

Conclusions: Plasma exchange (PE) was associated with clinical improvement in 63% of patients at 6 months. Early initiation of PE and improvement at discharge were predictors of this response. Twelve patients (48%) who did not improve early did so during follow-up.

Abbreviations: CI = confidence interval; CIS = clinically isolated demyelinating syndrome; EDSS = Expanded Disability Status Scale; MS = multiple sclerosis; NA = not applicable; NMO = neuromyelitis optica; non-MS = excludes multiple sclerosis and clinically isolated syndrome; ON = optic neuritis; OR = odds ratio; PE = plasma exchange; VA = visual acuity.

Supplemental data at www.neurology.org

*These authors had equal participation in the study.

Supported in part by grant PI060070, Fondo de Investigaciones Sanitarias, Madrid, Spain (A.S.), and Red Española de Esclerosis Múltiple (F.G., RD07/0060/0012; X.M., RD07/0060/0020; L.R.-T., RD07/0060/002), Instituto de Salud Carlos III, Madrid, Spain.

Disclosure: Author disclosures are provided at the end of the article.

Received April 7, 2009. Accepted in final form June 30, 2009.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by AAN Enterprises, Inc.